Clinical Trial Update: Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating cadonilimab in combination with lenvatinib as neoadjuvant therapy for clear cell renal cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• Cadonilimab
• Lenvatinib (lenvatinib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Clear Cell Renal Cell Carcinoma | Phase 2 | Status: COMPLETED